Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer (Q36589857)

15 August 2017

1 reference

title

Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer (English)

1 reference

15 August 2017

1 reference

1 reference

1 reference

1 reference

Jonathan W Simons

1

1 reference

PubMed ID

16962494

15 August 2017

Natalie Sacks

series ordinal

2

1 reference

15 August 2017

1 September 2006

1 reference

15 August 2017

6

1 reference

based on heuristic

inferred from page(s)

published in

Urologic Oncology

1 reference

15 August 2017

24

1 reference

15 August 2017

5

1 reference

15 August 2017

419-424

1 reference

Demonstration of a rational strategy for human prostate cancer gene therapy

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.021

Is cancer dangerous to the immune system?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.021

Uses of granulocyte-macrophage colony-stimulating factor in vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.021

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.021

The central role of CD4(+) T cells in the antitumor immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.021

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.021

Gene therapy and molecular immunology unite to give new life to cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.021

Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.021

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.021

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.021

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.021

Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.021

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLONC.2005.08.021

1 reference

15 August 2017

1 reference

PubMed ID

16962494